Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 58, Issue 8, 1998, Pages 625-634

  Lillestol I K ^a   Helle, K B ^a   Aardal, Sidsel ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Calcium channel blockers; cAMP; cGMP; ET 1; Phosphodiesterases; Porcine LAD

Indexed keywords

8 BROMO CYCLIC AMP; 8 BROMO CYCLIC GMP; ATRIAL NATRIURETIC FACTOR; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; ENDOTHELIN 1; FORSKOLIN; ISRADIPINE; MILRINONE; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; VASODILATOR AGENT; VERAPAMIL; VINPOCETINE; ZAPRINAST;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; DRUG POTENCY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALIA; SUIDAE; SUS SCROFA;

EID: 0009754691     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519850186058     Document Type: Article

References (49)

1. 1 Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
2. 2 Yanagisawa MH, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells [see comments]. Nature 1988; 332: 411-5.
3. 2+ channels. In Morad M, Nayler W, Kazada S, Schramm M, editors. The calcium channel: structure function and implications. Berlin/Heidelberg: Springer-Verlag, 1988: 575-83.
4. 4 Wagner Mann C, Sturek M. Endothelin mediates Ca influx and release in porcine coronary smooth muscle cells Am J Physiol 1991; 260: C771-7.
5. 5 Kodama M, Kanaide H, Abe S, Hirano K, Kai H, Nakamura M. Endothelin-induced Ca-independent contraction of the porcine coronary artery. Biochem Biophys Res Commun 1989; 160: 1302-8.
6. 6 Abe Y, Kasuya Y, Kudo M, Yamashita K, Goto K, Masaki T, Takuwa Y. Endothelin-1-induced phosphorylation of the 20-kDa myosin light chain and caldesmon in porcine coronary artery smooth muscle. Jpn J Pharmacol 1991; 57: 431-5.
7. 7 Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995; 29: 805-12.
8. 8 Vegesna RV, Diamond J. Elevation of cyclic AMP by prostacyclin is accompanied by relaxation of bovine coronary arteries and contraction of rabbit aortic rings. Eur J Pharmacol 1986; 128: 25-31.
9. 9 Kelly RA, Smith TW. Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol 1996; 77: 2C-7C.
10. 10 Goldberg ND, O'Dea RF, Haddox MK. Cyclic GMP. Adv Cyclic Nucleotide Res 1973; 3: 155-223.
11. 11 Napoli SA, Gruetter CA, Ignarro LJ, Kadowitz PJ. Relaxation of bovine coronary arterial smooth muscle by cyclic GMP, cyclic AMP and analogs. J Pharmacol Exp Ther 1979; 212: 469-73.
12. 12 Opie LH. Calcium channel antagonist in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996; 38: 273-90.
13. 13 Kai H, Kanaide H, Matsumoto T, Shogakiuchi Y, Nakamura M. Adenosine decreases intracellular free calcium concentrations in cultured vascular smooth muscle cells from rat aorta. FEBS Lett 1987; 212: 119-22.
14. 14 Walter U, Waldmann R, Nieberding M. Intracellular mechanism of action of vasodilators. Eur Heart J 1988; 9 Suppl H: 1-6.
15. 15 Pagani ED, Buchholz RA, Silver PJ. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. Basic Res Cardiol 1992; 87 Supp. 1: 73-86.
16. 16 Lindgren S, Andersson KE. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. Acta Physiol Scand 1991; 142: 77-82.
17. 17 Chen XL, Rembold CM. Cyclic nucleotide-dependent regulation of Mn2+ influx, [Ca2+]i, and arterial smooth muscle relaxation. Am J Physiol 1992; 263: C468-73.
18. 18 Xiong Z, Sperelakis N. Regulation of L-type calcium channels of vascular smooth muscle cells. J Mol Cell Cardiol 1995; 27: 75-91.
19. 19 Twort CH, van Breemen C. Cyclic guanosine monophosphate-enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988; 62: 961-4.
20. 20 Rashatwar SS, Cornwell TL, Lincoln TM. Effects of 8-bromo-cGMP on Ca2+ levels in vascular smooth muscle cells: possible regulation of Ca2+-ATPase by cGMP-dependent protein kinase. Proc Natl Acad Sci USA. 1987; 84: 5685-9.
21. 21 Conti MA, Adelstein RS. The relationship between calmodulin binding and phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3′:5′ cAMP-dependent protein kinase. J Biol Chem 1981; 256: 3178-81.
22. 22 de Lanerolle P, Nishikawa M, Yost DA, Adelstein RS. Increased phosphorylation of myosin light chain kinase after an increase in cyclic AMP in intact smooth muscle. Science 1984; 223: 1415-7.
23. 23 Yanagisawa T, Kawada M, Taira N. Nitroglycerin relaxes canine coronary arterial smooth muscle without reducing intracellular Ca2+ concentrations measured with fura-2. Br J Pharmacol 1989; 98: 469-82.
24. 24 Opgaard OS, Adner M, Gulbenkian S, Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol 1994; 23: 576-83.
25. 25 Kalsner S. Cholinergic mechanisms in human coronary artery preparations: implications of species differences. J Physiol Lond 1985; 358: 509-26.
26. 26 Absood A, Chen D, Hakanson R. Neuropeptides of the vasoactive intestinal peptide/helodermin/ pituitary adenylate cyclase activating peptide family elevate plasma cAMP in mice: comparison with a range of other regulatory peptides. Regul Pept 1992; 40: 311-22.
27. 27 Seo B, Lüscher TF. ETA and ETB receptors mediate contraction to endothelin-1 in renal artery of aging SHR. Effects of FR139317 and bosentan. Hypertension 1995; 25: 501-6.
28. 28 Ohbayashi A, Hiraga T, Okubo M, Murase T, Matsushita H, Hara M. Characteristics of porcine coronary artery endothelial cells in culture: comparison with aortic endothelium. Biochem Biophys Res Commun 1994; 202: 504-11.
29. 29 Highsmith RF, Blackburn K, Schmidt DJ. Endothelin and calcium dynamics in vascular smooth muscle. Annu Rev Physiol 1992; 54: 257-77.
30. 30 Hubel CA, Highsmith RF. Endothelin-induced changes in intracellular pH and Ca2+ in coronary smooth muscle: role of Na(+)-H+ exchange. Biochem J 1995; 310: 1013-20.
31. 31 Fitton A, Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990; 40: 31-74.
32. 32 McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989; 38: 19-76.
33. 33 Omland T, Bonarjee VV, Aakvaag A, Aarsland T, Dickstein K. The relationship between early plasma atrial natriuretic factor levels and exercise performance after myocardial infarction. Eur Heart J 1993; 14: 1022-6.
34. 34 Öye BK, Hoff P, Skadberg B, Tronstad A, Myking O, Aakvaag A. Atrial natriuretic peptide from the coronary sinus is acutely increased following induction of paroxysmal tachycardia. JACC 1989; 13: 177A.
35. 35 Dewar ML, Walsh G, Chiu RC, Kochamba G, Gutkowska J, Genest J, Cantin M. Atrial natriuretic factor: response to cardiac operation. J Thorac Cardiovasc Surg 1988; 96: 266-70.
36. 36 Espiner EA, Nicholls MG, Yandle TG, Crozier IG, Cuneo RC, McCormick D, Ikram H. Studies on the secretion, metabolism and action of atrial natriuretic peptide in man. J Hypertens Suppl 1986; 4: S85-91.
37. 37 Kawasaki J, Kobayashi S, Miyagi Y, Nishimura J, Fujishima M, Kanaide H. The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery. Br J Pharmacol 1997; 121: 977-85.
38. 38 Fukuizumi Y, Kobayashi S, Nishimura J, Kanaide H. The effects of calcitonin gene-related peptide on the cytosolic calcium concentration and force in the porcine coronary artery. J Pharmacol Exp Ther 1996; 278: 220-31.
39. 39 Nakashima M, Morrison KJ, Vanhoutte PM. Hyperpolarization and relaxation of canine vascular smooth muscle to vasoactive intestinal polypeptide. J Cardiovasc Pharmacol 1997; 30: 273-7.
40. 40 Jiang H, Colbran JL, Francis SH, Corbin JD. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 1992; 267: 1015-9.
41. 41 Waldman SA, Murad F. Atrial natriuretic peptides: receptors and second messengers. Bioessays 1989; 10: 16-9.
42. 42 Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci 1989; 10: 442-7.
43. 43 Poison JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996; 36: 403-27.
44. 44 Lincoln TM, Cornwell TL, Taylor AE. cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. Am J Physiol 1990; 258: C399-407.
45. 45 Lincoln TM, Cornwell TL. Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 1991; 28: 129-37.
46. 2+ desensitization of skinned rat artery. Eur J Pharmacol 1997; 323: 75-82.
47. 47 Polson JB, Cyclic nucleotide phosphodiesterases. Possible targets for new drugs. J Fla Med Assoc 1990; 77: 1045-6.
48. 48 Lindgren S, Rascon A, Andersson KE, Manganiello V, Degerman E. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem Pharmacol 1991; 42: 545-52.
49. 49 Suzuki S, Kajikuri J, Suzuki A, Itoh T. Effects of endothelin-1 on endothelial cells in the porcine coronary artery. Circ Res 1991; 69: 1361-8.